Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy  Ulrich R. Müller, MD, Marek Jutel, MD,

Slides:



Advertisements
Similar presentations
Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.
Advertisements

In situ imaging of honeybee (Apis mellifera) venom components from aqueous and aluminum hydroxide–adsorbed venom immunotherapy preparations Ulla Seppälä,
Impaired TH17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy 
D-dimer: A biomarker for antihistamine-resistant chronic urticaria
Triggering of specific Toll-like receptors and proinflammatory cytokines breaks allergen- specific T-cell tolerance in human tonsils and peripheral blood 
Allergen immunotherapy: A practice parameter third update
Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2  Natalija Novak, MD, Nihal Mete, MD, Caroline.
Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus.
Alexandra Kazaks, MA, RD, Janet Y. Uriu-Adams, PhD, Judith S
Russell S. Traister, MD, PhD, Crystal E. Uvalle, BS, Gregory A
Advances in food allergy in 2015
Advances and highlights in allergen immunotherapy: On the way to sustained clinical and immunologic tolerance  Margot Berings, MD, Cagatay Karaaslan,
Impaired TH17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy 
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Atopic dermatitis: Age and race do matter!
Erika Lerch, MD, Ulrich R. Müller, MD 
The Editors' Choice Journal of Allergy and Clinical Immunology
T-cell regulation during viral and nonviral asthma exacerbations
Is 9 more than 2 also in allergic airway inflammation?
Joe K. Gerald, MD, PhD, Roni Grad, MD, William C. Bailey, MD, Lynn B
Triggering of specific Toll-like receptors and proinflammatory cytokines breaks allergen- specific T-cell tolerance in human tonsils and peripheral blood 
Histamine in the immune regulation of allergic inflammation
T-cell regulation in chronic paranasal sinus disease
Staphylococcus aureus enhances the tight junction barrier integrity in healthy nasal tissue, but not in nasal polyps  Can Altunbulakli, MSc, Rita Costa,
Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J
The Editors' Choice Journal of Allergy and Clinical Immunology
Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus.
Physician needs in health informatics: Just ask the docs
Targeting Fel d 1 to FcγRI induces a novel variation of the TH2 response in subjects with cat allergy  Kathryn E. Hulse, BS, Amanda J. Reefer, MS, Victor.
Elina Jerschow, MD, MSc, Robert Y. Lin, MD, MSc, Moira M
Peter M. Wolfgram, MD, David B. Allen, MD 
The future of allergy/immunology: Promising young investigators
Possible role of TH17 cells in the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis  Yuichi Teraki, MD, Misaki Kawabe, MD, Seiichi.
Phillip Lieberman, MD, Michael Tankersley, MD 
Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation  Leif Bjermer, MD  Journal of Allergy.
News & Notes Journal of Allergy and Clinical Immunology
Phillip Lieberman, MD, David Golden, MD 
Histamine receptor 2 is a key influence in immune responses to intestinal histamine- secreting microbes  Ruth Ferstl, PhD, Remo Frei, PhD, Elisa Schiavi,
Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management  Scott H. Sicherer, MD, Hugh A. Sampson, MD  Journal.
Biosimilars and drug development in allergic and immunologic diseases
Allergen-specific immunotherapy with recombinant grass pollen allergens  Marek Jutel, MD, Lothar Jaeger, MD, Roland Suck, PhD, Hanns Meyer, Dipl Math,
A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity  Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,
Claus Bachert, MD, PhD, Cezmi A. Akdis, MD 
Cephalosporin Side Chain Cross-reactivity
Liam O’Mahony, PhD, Mübeccel Akdis, MD, PhD, Cezmi A. Akdis, MD 
Enhanced CD46-induced regulatory T cells suppress allergic inflammation after Dermatophagoides pteronyssinus–specific immunotherapy  Yi-Giien Tsai, MD,
Direct ex vivo analysis of allergen-specific CD4+ T cells
Autophagy: Nobel Prize 2016 and allergy and asthma research
Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment
Lei Wang, MD, PhD, Jesse P. Joad, MD, Caiyun Zhong, MD, PhD, Kent E
A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy  Fatimah Kussebi, MD, Fariba Karamloo, PhD, Claudio Rhyner,
Geographic variability in childhood asthma prevalence in Chicago
Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy?  Marianne Witten, MD, PhD, Hans-Jørgen Malling, MD, Lars.
Matthew J. Loza, PhD, Susan Foster, PhD, Stephen P
Alexandra Kazaks, MA, RD, Janet Y. Uriu-Adams, PhD, Judith S
Wasp venom immunotherapy expands a subpopulation of CD4+CD25+ forkhead box protein 3–positive regulatory T cells expressing the T-cell receptor Vβ2 and.
IL-10–producing monocytes differentiate to alternatively activated macrophages and are increased in atopic patients  Antje Prasse, MD, Martin Germann,
Macrolide antibiotics and asthma treatment
The Editors' Choice Journal of Allergy and Clinical Immunology
Asthma: The past, future, environment, and costs
Julie Negri, BA, S. Brandon Early, BA, John W
Epicutaneous immunization with ovalbumin and CpG induces TH1/TH17 cytokines, which regulate IgE and IgG2a production  Monika Majewska-Szczepanik, PhD,
IgG4 production is confined to human IL-10–producing regulatory B cells that suppress antigen-specific immune responses  Willem van de Veen, MSc, Barbara.
Environmental factors and eosinophilic esophagitis
Sublingual immunotherapy for peanut allergy: Clinical and immunologic evidence of desensitization  Edwin H. Kim, MD, J. Andrew Bird, MD, Michael Kulis,
News Beyond Our Pages Journal of Allergy and Clinical Immunology
Regulation of bronchial epithelial barrier integrity by type 2 cytokines and histone deacetylases in asthmatic patients  Paulina Wawrzyniak, MSc, Marcin.
Natural history of cow’s milk allergy
The Editors’ Choice Journal of Allergy and Clinical Immunology
Primary prevention of asthma and allergy
Presentation transcript:

Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy  Ulrich R. Müller, MD, Marek Jutel, MD, Andrea Reimers, MD, Judith Zumkehr, Sci Tec, Clarissa Huber, MD, Carola Kriegel, MD, Urs Steiner, MD, Gabrielle Haeberli, MD, Mübeccel Akdis, MD, PhD, Arthur Helbling, MD, Benno Schnyder, MD, Kurt Blaser, PhD, Cezmi Akdis, MD  Journal of Allergy and Clinical Immunology  Volume 122, Issue 5, Pages 1001-1007.e4 (November 2008) DOI: 10.1016/j.jaci.2008.08.007 Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 BV sIgE and sIgG antibodies and PLA-stimulated proliferation of PBMCs during ultrarush BVIT. A, sIgE levels did not change significantly, although there was a highly significant increase of sIgG levels in both groups. B, PLA-stimulated proliferation decreased in both groups, but the reduction reached significance only in the LC group on day 110. P, Placebo. Journal of Allergy and Clinical Immunology 2008 122, 1001-1007.e4DOI: (10.1016/j.jaci.2008.08.007) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Cytokine secretion in PLA-stimulated PBMC cultures during BVIT. A, IFN-γ levels decreased significantly more in the placebo group on day 21. B, IL-13 levels decreased in both groups between before BVIT and day 110 but significantly more in the placebo group. C, IL-10 levels increased significantly on day 21 compared with those before BVIT in the LC group. P, Placebo. Journal of Allergy and Clinical Immunology 2008 122, 1001-1007.e4DOI: (10.1016/j.jaci.2008.08.007) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Effect of BVIT on HR expression in PLA-stimulated T cells. A, HR1 mRNA expression. B, HR2 mRNA expression. C, HR1/HR2 mRNA expression ratio. Although no significant difference in HR1 and HR2 expression is observed between groups, the HR1/HR2 ratio is significantly lower in the placebo group on day 21. P, Placebo. Journal of Allergy and Clinical Immunology 2008 122, 1001-1007.e4DOI: (10.1016/j.jaci.2008.08.007) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions